sansrosa articles ↓

According to the just published earnings call, Collagenex have been asked to undertake a additional Phase 2 study before commencing Phase 3. These additional studies will take several months, delaying the start of Phase 3. Collagenex are still hopeful of commencing Phase 3 studies some time before the end of 2008. These additional studies are to confirm that the diseased rosacea skin does not …

Regarding another investor conference today, CEO Colin Stewart presented and most of the information was familiar. However, during the question period, an audience member asked about rebound flushing/redness during the Sansrosa / COL-118 trials. The following is what was said:

Man: “I realize that it’s an in-class, COL-118, it’s kind of difficult to work out the economics of the opportunity. Now, the fact …

This poster abstract is an update to the paper that was published in Archives of Dermatology in 2007 and was covered by Rosacea News as Sansrosa’s sister to enter redness race. This now expanded abstract suggests that oxymetazoline is effective for up to 6 hours after application and no side effects have been seen after 3 months usage. …

A recent investor presentation from Collagenex gives some hints as to how Collagenex will price COL-118. Collagenex believe that their anti erythema product used for  2-4 months of treatment at $150 a month leads to a $330-660 million market. $150 a month for COL-118 treatment sounds like a lot. One wonders how much the suggested $150 a month will translate to at the …

PubMed pushed out an interesting abstract in the last couple of days. A bit of digging reveals what looks to be a running mate for COL-118/Sansrosa. COL-118 and Oxymetazoline appear to be promoted by separate groups of researchers.

This is good news for rosacea sufferers as it means there may well be a choice between 2 topicals that can help address the redness and flushing …